Labat AfricaJSE:LAB EV-to-EBIT is 1.12 as of Jul. 06, 2026. The stock has 5 warning signs investors should review. Among 689 Drug Manufacturers companies, Labat Africa ranks better than 96.08% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Labat Africa's Enterprise Value for the quarter that ended in Nov. 2025 was R204.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labat Africa's EBIT for the trailing twelve months (TTM) ended in Nov. 2025 was R208.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labat Africa EV-to-EBIT Related Terms
Labat Africa EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Labat Africa's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Labat Africa's EV-to-EBIT falls into.
Labat Africa's current Enterprise Value is R232.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labat Africa's EBIT for the trailing twelve months (TTM) ended in Nov. 2025 was R208.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labat Africa (JSE:LAB) has a EV-to-EBIT of 1.12 as of Jul. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #27 out of 689 companies in the Drug Manufacturers industry, placing it in the top 3.9%.
Is Labat Africa's EV-to-EBIT too high?
Labat Africa's current EV-to-EBIT is 1.12. The Drug Manufacturers industry median EV-to-EBIT is 16.01. Labat Africa's value of 1.12 is 93% below this industry median. Based on the distribution chart, Labat Africa ranks #27 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #27 out of 689 companies for EV-to-EBIT. This places Labat Africa in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.01. Labat Africa's value of 1.12 is 93% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current EV-to-EBIT of 1.12 is 93% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current EV-to-EBIT is 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.04 — trading 77.8% below its estimated fair value. The current EV-to-EBIT is 1.12 and 93% below the Drug Manufacturers industry median of 16.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current EV-to-EBIT is 1.12 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 